RT Journal Article
SR Electronic
T1 Cost-effectiveness analysis comparing repetitive transcranial magnetic stimulation therapy with antidepressant treatment in patients with treatment-resistant depression in Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.02.22282995
DO 10.1101/2022.12.02.22282995
A1 Noda, Yoshihiro
A1 Miyashita, Chiaki
A1 Komatsu, Yoko
A1 Kito, Shinsuke
A1 Mimura, Masaru
YR 2022
UL http://medrxiv.org/content/early/2022/12/06/2022.12.02.22282995.abstract
AB Background In Japan, repetitive transcranial magnetic stimulation (rTMS) for patients with treatment-resistant depression (TRD) became covered by the National Health Insurance (NHI) in 2019. While the usefulness of rTMS for TRD has been established, the cost-effectiveness of rTMS versus antidepressants has not been thoroughly analyzed in Japan. This study aimed to evaluate the cost-effectiveness of rTMS for TRD under the NHI system.Methods Cost-effectiveness of rTMS versus antidepressants was analyzed using a microsimulation model to compare the direct costs and quality-adjusted life years (QALYs) in patients with moderate to severe depression who had failed one or more antidepressants over their lifetime. Model inputs of clinical parameters and the utility were derived from published literature. Cost parameters were estimated from the Japanese Claim Database. In addition, the robustness of the analysis results was evaluated using sensitivity analysis and scenario analysis.Results The analysis estimated that rTMS increased effectiveness by 0.101QALYs and total cost by ¥94,370 ($689) compared with antidepressant medications. As a result, the incremental cost-effectiveness ratio (ICER) of rTMS was estimated to be ¥935,984 ($6,832)/QALY. In the sensitivity and scenario analyses, ICER did not exceed ¥5 million ($36,496)/QALY as the reference value of the Japanese public cost-effectiveness evaluation system.Limitations For the portion of the rTMS for which data were not available under the NHI system in Japan, foreign data and estimates were extrapolated.Conclusions rTMS showed the potential to be a cost-effective treatment strategy for TRD compared with antidepressants under the NHI system in Japan.Competing Interest StatementThe authors declare no conflicts of interest associated with this manuscript. CM and YK are employed by Teijin Pharma Limited.Funding StatementThis study was supported by Teijin Pharma Limited (Tokyo, Japan). The sponsor had no control over the interpretation, writing, or publication of this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online